Empirical Bioscience announced today that their QuantiTASE and QuantiTASE PLUS One Step RT-qPCR RT-qPCR Kits have been successfully tested in assays using EUA authorized qPCR detection kits using the established CDC testing protocol.
The test amplifies and identifies genetic material from the SARS-CoV-2 virus that causes COVID-19 in one step. The QuantiTASE RT-qPCR Assay Kits works by converting the CoV-2 RNA into DNA and amplifying to detect the presence of pathogenic material in patient samples.
In addition to its efficient design, the kit operates on most existing laboratory testing equipment in the United States, and it includes all of the required RT-qPCR reaction reagents needed to run a COVID-19 test. It also meets the performance requirements for nCoV-2 testing established by the Centers for Disease Control (CDC) when used in accordance with CDC guidelines and in conjunction with an approved detection kit.
The kit’s attributes lend themselves well to the growing need for real-time COVID-19 testing. The company expects the demand for the kits to continue accelerating and they’ve adjusted their production and delivery time accordingly. “We are ramping up our production capacity from 50,000 kits a week to 100,000 a week,” said Des O’Farrell, President of Empirical Bioscience. “We are also offering 24 hour shipping.”
Besides the QuantiTASE RT-qPCR Kit, the company also offers a full range of Molecular Biology reagents to original equipment manufacturers (OEM) and laboratories to support their testing and research. Other Empirical Bioscience products being used in the fight against COVID-19 and other viral pathogens include, RTScript™ Reverse Transcriptase, DNA Polymerases, Custom MasterMix solutions and sample processing kits for RNA extraction and preparation.
Empirical Bioscience produces high-grade reagents and enzymes for Molecular Biology applications in its ISO 13485:2016 certified and FDA Registered facility in Grand Rapids, MI, USA and is a Registered Small Business Company.